Most Read Articles
02 Aug 2020
In heartburn patients who do not respond to proton pump inhibitor (PPI) treatment, the oesophageal radiofrequency procedure falls short of relieving symptoms and reducing PPI use, a study has shown.
Stephen Padilla, 3 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
6 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.
3 days ago
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.

Inhalable mRNA dry powder promising for lung disease management

Christina Lau
21 Nov 2019

An inhalable dry powder formulation of mRNA developed by researchers at the University of Hong Kong has shown promise in the treatment of lung diseases.

The formulation was developed using PEG12KL4, a pegylated cationic peptide, as RNA delivery vector. With the use of spray drying and spray freeze drying techniques, PEG12KL4/mRNA complexes were formulated into dry powder with satisfactory aerosol properties for inhalation. [J Control Release 2019;314:102-115]

Intratracheal administration of luciferase mRNA using the above formulation resulted in luciferase expression in the deep lung region of mice 24 hours post-transfection, with superior transfection efficiency compared with naked mRNA or lipoplexes, which led to weaker luciferase expression in the tracheal region only. No sign of inflammatory response or toxicity was reported with the PEG12KL4/mRNA complexes following a single intratracheal administration.

According to the investigators, the inhalable mRNA dry powder can potentially be used to treat lung diseases such as asthma, chronic obstructive pulmonary disease and cancer. The team is now developing an inhalable mRNA vaccine based on their discovery.

The inhalable mRNA dry powder is more stable and patient-friendly, with a lower treatment cost, compared with liquid formulations administered by nebulization using bulky devices, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Aug 2020
In heartburn patients who do not respond to proton pump inhibitor (PPI) treatment, the oesophageal radiofrequency procedure falls short of relieving symptoms and reducing PPI use, a study has shown.
Stephen Padilla, 3 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
6 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.
3 days ago
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.